- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Nectar Lifesciences shareholders have approved key resolutions at the EGM. Dr. Surulichamy Senthilkumar's appointment as a Director and Wholetime Director (R&D) for three years has been sanctioned, strengthening the company's research and development capabilities. Importantly, shareholders also gave their nod to the strategic transfer of a business segment to Ceph Lifesciences Private Limited on a 'slump sale' basis. This signifies a major operational restructuring approved by both special resolution and public shareholders, potentially reshaping the company's future focus and asset base.